Signet Financial Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-2,217
Closed -$97K 722
2021
Q4
$97K Buy
+2,217
New +$105K 0.01% 328

Other funds holding IDNA

Signet Financial Management's IDNA Position: Q1 2022 in Review

Signet Financial Management sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 2,217 shares — an estimated $97K sold.

Signet Financial Management first reported a position in IDNA in Q4 2021 and held it in 1 quarter. The position peaked at $97K in Q4 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.

  • Signet Financial Management reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 2,217 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $97K.
  • Signet Financial Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's iShares Genomics Immunology and Healthcare ETF position peaked at $97K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.